Ceftriaxone pharmacokinetics in newborn infants

Area of Science:

• Pediatric Pharmacology
• Infectious Disease Research
• Neonatal Pharmacokinetics

Background:

• Ceftriaxone is a widely used antibiotic in neonates.
• Understanding its pharmacokinetic profile in newborns is crucial for safe and effective dosing.

Purpose of the Study:

• To determine the pharmacokinetic parameters of ceftriaxone in newborn infants.
• To assess the impact of ceftriaxone on gut microbiota in this population.
• To propose an optimal dosing regimen for ceftriaxone in neonates.

Main Methods:

• Pharmacokinetic analysis in 40 newborn infants (1-45 days old).
• Intravenous infusion of 50 mg/kg ceftriaxone over 15 minutes.
• Measurement of peak plasma concentrations, half-life, and plasma clearance.
• Analysis of rectal swab cultures to evaluate changes in aerobic and anaerobic bacteria.

Main Results:

• Mean peak plasma concentrations ranged from 136 to 173 µg/ml.
• Mean half-life values were between 5.2 and 8.4 hours.
• Mean plasma clearance rates were 0.7 to 1.8 ml/min.
• Significant reduction or absence of aerobic and anaerobic bacteria was observed in 14 of 16 infants' rectal swabs.

Conclusions:

• Ceftriaxone exhibits predictable pharmacokinetics in newborn infants.
• A once-daily dosing schedule appears appropriate for ceftriaxone therapy in neonates.
• Ceftriaxone demonstrates antimicrobial activity against gut flora in infants.